Helminths at mucosal barriers - Interaction with the immune system

Advanced Drug Delivery Reviews

Volumn 56, Issue 6, 2004, Pages 853-868

  Mulcahy, Grace ^a   O'Neill, Sandra ^b   Donnelly, Sheila ^b   Dalton, J P ^a,c  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b DUBLIN CITY UNIVERSITY   (Ireland)

^c UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Helminth; Immunopathology; Mucosal immunity; Vaccine

Indexed keywords

CHEMOTHERAPY; MEDICAL PROBLEMS; PATHOLOGY; RESPIRATORY SYSTEM; TISSUE; VACCINES;

GASTRO-INTESTINAL TRACT (GIT); MORBIDITY; MORTALITY; MUCOSAL BARRIERS;

IMMUNOLOGY;

ANTIINFECTIVE AGENT; ANTIPARASITIC AGENT; BACTERIAL VACCINE; RECOMBINANT ANTIGEN; RECOMBINANT VACCINE; VACCINE; VIRUS VACCINE;

AUTOIMMUNITY; BACTERIAL INFECTION; BIOLOGY; CELL ACTIVITY; DRUG COST; DRUG EFFECT; ENVIRONMENTAL FACTOR; HELMINTH; HELMINTHIASIS; HOST; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOPROPHYLAXIS; INTESTINE INFECTION; INTESTINE MUCOSA; NONHUMAN; PARASITE; PATHOGENESIS; POLARIZATION; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA; REVIEW; TH2 CELL; TREATMENT PLANNING; VIRUS INFECTION;

EID: 1942439907     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2003.10.033     Document Type: Article

References (91)

1. Chen M.G., Mott K.E. Progress in assessment of morbidity due to Fasciola hepatica infection. A review of recent literature. Trop. Dis. Bull. 87:1990;1-38.
2. Dalton J.P., Brindley P.J., Knox D.P., Brady C.P., Hotez P.J., Donnelly S., O'Neill S.M., Mulcahy G., Loukas A. Helminth vaccines: from mining genomic information for vaccine targets to systems used for protein expression. Int. J. Parasitol. 33:2003;621-640.
3. Harrison L.M., Nerlinger A., Bungiro R.D., Cordova J.L., Kuzmic P., Cappello M. Molecular characterization of Ancylostoma inhibitors of coagulation factor Xa. Hookworm anticoagulant activity in vitro predicts parasite bloodfeeding in vivo. J. Biol. Chem. 277:2002;6223-6229.
4. Crompton D.W., Nesheim M.C. Nutritional impact of intestinal helminthiasis during the human life cycle. Annu. Rev. Nutr. 22:2002;35-59.
5. Lawrence C.E., Paterson J.C., Wei X.Q., Liew F.Y., Garside P., Kennedy M.W. Nitric oxide mediates intestinal pathology but not immune expulsion during Trichinella spiralis infection in mice. J. Immunol. 164:2000;4229-4234.
6. Balemba O.B., Mbassa G.K., Assey R.J., Kahwa C.K., Makundi A.E., Hay-Schmidt A., Dantzer V., Semuguruka W.D. Lesions of the enteric nervous system and the possible role of mast cells in the pathogenic mechanisms of migration of schistosome eggs in the small intestine of cattle during Schistosoma bovis infection. Vet. Parasitol. 2000;57-71.
7. Barbara G., Vallance B.A., Collins S.M. Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology. 113:1997;1224-1232.
8. Mukhopadhyay B., Saha S., Maiti S., Mitra D., Banerjee T.J., Jha M., Mukhopadhyay M., Samanta N., Das S. Clinical appraisal of Ascaris lumbricoides, with special reference to surgical complications. Pediatr. Surg. Int. 17:2001;403-405.
9. Tort J., Brindley P.J., Knox D., Wolfe K.H., Dalton J.P. Proteinases and associated genes of parasitic helminths. Adv. Parasitol. 43:1999;161-266.
10. Lloyd S., Kristensen S., Soulsby E.J. The effect of corticosteroid therapy on infection with Toxocara canis in dogs. Z. Parasitenkd. 66:1981;57-61.
11. Vallance B.A., Collins S.M. The effect of nematode infection upon intestinal smooth muscle function. Parasite Immunol. 5:1998;249-253.
12. Boitelle A., Scales H.E., Di Lorenzo C., Devaney E., Kennedy M.W., Garside P., Lawrence C.E. Investigating the impact of helminth products on immune responsiveness using a TCR transgenic adoptive transfer system. J. Immunol. 171:2003;447-454.
13. Quinnell R.J., Woolhouse M.E., Walsh E.A., Pritchard D.I. Immunoepidemiology of human necatoriasis: correlations between antibody responses and parasite burdens. Parasite Immunol. 17:1995;313-318.
14. Gasbarre R., Gasbarre L.C. Limiting dilution analyses for the quantification of cellular immune responses in bovine ostertagiasis. Vet. Parasitol. 20:1986;133-147.
15. Almeria S., Canals A., Zarlenga D.S., Gasbarre L.C. Quantification of cytokine gene expression in lamina propria lymphocytes of cattle following infection with Ostertagia ostertagi. J. Parasitol. 83:1997;1051-1055.
16. Baker D.G., Stott J.L., Gershwin L.J. Abomasal lymphatic lymphocyte subpopulations in cattle infected with Ostertagia ostertagi and Cooperia sp. Vet. Immunol. Immunopathol. 39:1999;467-473.
17. Balic A., Bowles V.M., Meeusen E.N. The immunobiology of gastrointestinal nematode infections in ruminants. Adv. Parasitol. 45:2000;181-241.
18. Winter M.D. Nematodirus battus 50 years on - a realistic vaccine candidate? Trends Parasitol. 18:2002;298-301.
19. Nawa Y., Ishikawa N., Tsuchiya K., Horii Y., Abe T., Khan A.I., Bing-Shi, Itoh H., Ide H., Uchiyama F. Selective effector mechanisms for the expulsion of intestinal helminths. Parasite Immunol. 16:1994;333-338.
20. Bozic F., Marinculic A., Durakovic E. Analysis of intestinal intraepithelial lymphocyte populations in experimental Trichinella spiralis infection of mice. Folia Parasitol. (Praha). 47:2000;55-59.
21. Hayday A., Tigelaar R. Immunoregulation in the tissues by gammadelta T cells. Nat. Rev. Immunol. 2003;233-242.
22. van der Kleij D., Latz E., Brouwers J.F., Kruize Y.C., Schmitz M., Kurt-Jones E.A., Espevik T., de Jong E.C., Kapsenberg M.L., Golenbock D.T., Tielens A.G., Yazdanbakhsh M. A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. J. Biol. Chem. 277:2002;48122-48129.
23. O'Neill S.M., Brady M.T., Callanan J.J., Mulcahy G., Joyce P., Mills K.H., Dalton J.P. Fasciola hepatica infection downregulates Th1 responses in mice. Parasite Immunol. 22:2000;147-155.
24. Clery D., Torgerson P., Mulcahy G. Immune responses of chronically infected adult cattle to Fasciola hepatica. Vet. Parasitol. 62:1996;71-82.
25. Capron A., Riveau G.J., Bartley P.B., McManus D.P. Prospects for a schistosome vaccine. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2:2002;281-290.
26. Pearce E.J., La Flamme A., Sabin E., Brunet L.R. The initiation and function of Th2 responses during infection with Schistosoma mansoni. Adv. Exp. Med. Biol. 452:1998;67-73.
27. Abraham D., Lucius R., Trees A.J. Immunity to Onchocerca spp. in animal hosts. Trends Parasitol. 18:2002;164-171.
28. Grzych J.M., Pearce E., Cheever A., Caulada Z.A., Caspar P., Heiny S., Lewis F., Sher A. Egg deposition is the major stimulus for the production of Th2 cytokines in murine Schistosomiasis mansoni. J. Immunol. 146:1991;1322-1327.
29. Aime N., Haque A., Bonnel B., Torpier G., Capron A. Neutrophil-mediated killing of Dipetalonema viteae microfilariae: simultaneous presence of IgE, IgG antibodies and complement is required. Immunology. 51:1984;585-594.
30. Heath D.D., Holcman B., Shaw R.J. Echinococcus granulosus: the mechanism of oncosphere lysis by sheep complement and antibody. Int. J. Parasitol. 24:1994;929-935.
31. Rickard M.D., Mackinlay L.M., Kane G.J., Matossian R.M., Smyth J.D. Studies on the mechanism of lysis of Echinococcus granulosus protoscoleces incubated in normal serum. J. Helminthol. 51:1977;221-228.
32. Marikovsky M., Arnon R., Fishelson Z. Proteases secreted by transforming schistosomula of Schistosoma mansoni promote resistance to killing by complement. J. Immunol. 1141:1998;273-278.
33. Diaz A., Ferreira A., Sim R.B. Complement evasion by Echinococcus granulosus: sequestration of hostfactor H in the hydatid cyst. J. Immunol. 158:1997;3779-3786.
34. Horstmann R.D. Target recognition failure by the nonspecific defence system: surface constituents of pathogens interfere with the alternative pathway of complement activation. Infect. Immun. 60:1992;721-727.
35. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science. 271:1996;348-350.
36. Green T.D., Newton B.R., Rota P.A., Xu Y., Robinson H.L. Ross C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine. 20:2001;242-248.
37. Ross T.M., Xu Y., Bright R.A., Robinson H.L. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat. Immunol. 1:2000;127-131.
38. van Dam G.J., Seino J., Rotmans J.P., Daha M.R., Deelder A.M. Schistosoma mansoni circulating anodic antigen but not circulating cathodic antigen interacts with complement component C1q. Eur. J. Immunol. 23:1993;2807-2812.
39. Weller A. Paramyosin inhibits complement C1. J. Immunol. 148:1992;124-128.
40. Celik I., Stover C., Botto M., Thiel S., Tzima S., Kunkel D., Walport M., Lorenz W., Schwaeble W. Role of the classical pathway of complement activation in experimentally induced polymicrobial peritonitis. Infect. Immun. 69:2001;7304-7309.
41. Warren J., Mastroeni P., Dougan G., Noursadeghi M., Cohen J., Walport M.J., Botto M. Increased susceptibility of C1q-deficient mice to Salmonella enterica serovar Typhimurium infection. Infect. Immun. 70:2002;551-557.
42. Piedrafita D., Spithill T.W., Dalton J.P., Brindley P.J., Sandeman M.R., Wood P.R., Parsons J.C. Juvenile Fasciola hepatica are resistant to killing in vitro by free radicals compared with larvae of Schistosoma mansoni. Parasite Immunol. 22:2000;287-295.
43. Ou X., Thomas R., Chacon M.R., Tang L., Selkirk M.E. Brugia malayi: differential susceptibility to and metabolism of hydrogen peroide in adults and microfilariae. Exp. Parasitol. 80:1995;530-540.
44. Zang X.X., Yaxdanbakhsh M., Kiang H., Kanost M.R., Maizels R.M. A novel serpin expressed by the blood-borne microfilariae of the parasitic nematode Brugia malayi inhibits human neutrophil serine proteinases. Blood. 94:1999;1418-1428.
45. Bozas S.E., Panaccio M., Creaney J., Dosen M., Parsons J.C., Vlasuk G.V., Walker I., Spithill T.W. Characterisation of a novel Kuntiz-type molecule from trematode Fasciola hepatica. Mol. Biochem. Parasitol. 74:1995;19-24.
46. Kageyama T. Molecular cloning, expression and characterization of an Ascaris inhibitor for pepsin and cathepsin E. Eur. J. Biochem. 253:1998;804-809.
47. Bennett K., Levine T., Ellis J.S., Peanasky R.J., Samloff I.M., Kay J., Chain B.M. Antigen processing for presentation by class II major histocompatibility complex requires cleavage by cathepsin E. Eur. J. Immunol. 22:1992;1519-1524.
48. MacDonald A.S., Loke P., Martynoga R., Dransfield I., Allen J.E. Cytokine-dependent inflammatory cell recruitment patterns in the peritoneal cavity of mice exposed to the parasitic nematode Brugia malayi. Med. Microbiol. Immunol. (Berlin). 192:2003;33-40.
49. MacDonald A.S., Straw A.D., Dalton N.M., Pearce E.J. Cutting edge: Th2 response induction by dendritic cells: a role for CD40. J. Immunol. 168:2002;537-540.
50. Faveeuw C., Mallevaey T., Paschinger K., Wilson I.B., Fontaine J., Mollicone R., Oriol R., Altmann F., Lerouge P., Capron M., Trottein F. Schistosome N-glycans containing core alpha 3-fucose and core beta 2-xylose epitopes are strong inducers of Th2 responses in mice. Eur. J. Immunol. 33:2003;1271-1281.
51. Brady M.T., O'Neill S.M., Dalton J.P., Mills K.H.G. Fasciola hepatica suppresses a protective Th1 response against Bordetella pertussis. Infect. Immun. 67:1999;5372-5378.
52. Satoguina J., Mempel M., Larbi J., Badusche M., Loliger C., Adjei O., Gachelin G., Fleischer B., Hoerauf A. Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis). Microb. Infect. 13:2002;1291-1300.
53. Marshall M.A., Jankovic D., Maher V.E., Sher A., Berzofsky J.A. Mice infected with Schistosoma mansoni develop a novel non-T-lymphocyte suppressor population which inhibits virus-specific CTL induction via a soluble factor. Microb. Infect. 13:2001;1051-1061.
54. Beyers A.D., van Rie A., Adams J., Fenhalls G., Gie R., Beyers N. Signals that regulate the host response to Mycobacterium tuberculosis. Novartis Found Symp. 217:1998;145-157.
55. Bassily S., Dunn M.A., Farid Z., Kilpatrick M.E., El-Masry N.A., Kamel I.A., El Alamy M., Murphy B.L. Chronic hepatitis B in patients with schistosomiasis mansoni. J. Trop. Med. Hyg. 86:1983;67-71.
56. Madwar M.A., el Tahawy M., Strickland G.T. The relationship between uncomplicated schistosomiasis and hepatitis B infection. Trans. R. Soc. Trop. Med. Hyg. 83:1989;233-236.
57. McClary H., Koch R., Chisari F.V., Guidotti L.G. Inhibition of hepatitis B virus replication during Schistosoma mansoni infection in transgenic mice. J. Exp. Med. 192:2000;289-294.
58. Bentwich Z., Kalinkovich A., Weisman Z., Borkow G., Beyers N., Beyers A.D. Can eradication of helminthic infections change the face of AIDS and tuberculosis? Immunol. Today. 20:1999;485-487.
59. Galai N., Kalinkovich A., Burstein R., Vlahov D., Bentwich Z. African HIV-1 subtype C and rate of progression among Ethiopian immigrants in Israel. Lancet. 349:1997;180-181.
60. Muniz-Junqueira M.I., Tavares-Neto J., Prata A., Tosta C.E. Antibody response to Salmonella typhi in human schistosomiasis mansoni. Rev. Soc. Bras. Med. Trop. 29:1996;441-445.
61. Rougemont A., Boisson-Pontal M.E., Pontal P.G., Gridel F., Sangare S. Tuberculin skin tests and B.C.G. vaccination in hyperendemic area of onchocerciasis. Lancet. 1:(8006):1977;309.
62. Malhotra I., Mungai P., Wamachi A., Kioko J., Ouma J.H., Kazura J.W., King C.L. Helminth- and Bacillus Calmette-Guerin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. J. Immunol. 162:1999;6843-6848.
63. Sabin E.A., Araujo M.I., Carvalho E.M., Pearce E.J. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni. J. Infect. Dis. 173:1996;269-272.
64. Haseeb M.A., Craig J.P. Suppression of the immune response to diphtheria toxoid in murine schistosomiasis. Vaccine. 15:1997;45-50.
65. Kullberg M.C., Pearce E.J., Hieny S.E., Sher A., Berzofsky J.A. Infection with Schistosoma mansoni alters Th1/Th2 cytokine responses to a non-parasite antigen. J. Immunol. 148:1992;3264-3270.
66. + cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance. Proc. Natl. Acad. Sci. 90:1993;948-952.
67. Araujo F.G., Coelho P.M., Pereira L.H., Pellegrino J. Schistosoma mansoni: impairment of the cell-mediated immune response in mice. Clin. Exp. Immunol. 28:1977;289-291.
68. Muniz-Junqueira M.I., Tosta C.E., Prata A. T cell-dependent immunodepression in vivo in Schistosoma mansoni infected patients. Rev. Soc. Bras. Med. Trop. 23:1990;27-31.
69. O'Neill S.M., Mills K.H., Dalton J.P. Fasciola hepatica cathepsin L cysteine proteinase suppresses Bordetella pertussis-specific interferon-gamma production in vivo. Parasite Immunol. 23:2001;541-547.
70. Elliott D.E., Urban J.F.J.R., Argo C.K., Weinstock J.V. Does the failure to acquire helminthic parasites predispose to Crohn's disease? FASEB J. 14:2000;1848-1855.
71. Gale E.A. A missing link in the hygiene hypothesis? Diabetologia. 45:2000;588-594.
72. Palmas C., Gabriele F., Conchedda M., Bortoletti G., Ecca A.R. Causality or coincidence: may the slow disappearance of helminths be responsible for the imbalances in immune control mechanisms? J. Helminthol. 77:2002;147-153.
73. Todd J.A. A protective role of the environment in the development of type 1 diabetes? Diabetes Med. 8:1991;906-910.
74. Zaccone P., Fehervari Z., Jones F.M., Sidobre S., Kronenberg M., Dunne D.W., Cooke A. Schistosoma mansoni antigens modulate the activity of the innate immune response and prevent onset of type-1 diabetes. Eur. J. Immunol. 33:2003;1439-1449.
75. Troncone R., Franzese A., Mazzarella G., Paparo F., Auricchio R., Coto I., Mayer M., Greco L. Gluten sensitivity in a subset of children with insulin dependent diabetes mellitus. Am. J. Gastroenterol. 98:2003;590-595.
76. Simpson H.V. Pathophysiology of abomasal parasitism: is the host or parasite responsible? Vet. J. 160:2000;177-191.
77. Garside P., Kennedy M.W., Wakelin D., Lawrence C.E. Immunopathology of intestinal helminth infection. Parasite Immunol. 22:2000;605-612.
78. Sher A., Jankovic D., Cheever A., Wynn T. An IL-12-based vaccine approach for preventing immunopathology in schistosomiasis. Ann. New York Acad. Sci. 795:1996;202-207.
79. Johnson K.S., Harrison G.B., Lightowlers M.W., O'Hoy K.L., Cougle W.G., Dempster R.P., Lawrence S.B., Vinton J.G., Heath D.D., Rickard M.D. Vaccination against ovine cysticercosis using a defined recombinant antigen. Nature. 338:1989;585-587.
80. Lightowlers M.W. Vaccines for prevention of cysticercosis. Acta Trop. 87:2003;129-135.
81. Girod N., Brown A., Pritchard D.I., Billett E.E. Successful vaccination of BALB/c mice against human hookworm (Necator americanus): the immunological phenotype of the protective response. Int. J. Parasitol. 33:2003;1-80.
82. Mulcahy G., Dalton J.P. Cathepsin L proteinases as vaccines against infection with Fasciola hepatica (liver fluke) in ruminants. Res. Vet. Sci. 70:2001;83-86.
83. Mulcahy G., O'Connor F., McGonigle S., Dowd A., Clery D.G., Andrews S.J., Dalton J.P. Correlation of specific antibody titre and avidity with protection in cattle immunized against Fasciola hepatica. Vaccine. 16:1998;932-939.
84. McGuire C., Chan W.C., Wakelin D. Nasal immunisation with homogenate and peptide antigens induces protective immunity against Trichinella spiralis. Infect. Immun. 70:2002;7149-7152.
85. Toledo A., Fragoso G., Larralde C., Rosas G., Hernández M., Gevorkian G., López-Casillas F., Hernández B., Acero G., Huerta M., Sciutto E. Two epitopes shared by Taenia crassiceps and Taenia solium confer protection against murine T. crassiceps cysticercosis along with a prominent T1 response. Infect. Immun. 69:2001;1766-1773.
86. Williams S.A., Johnston D.A. Helminth genome analysis: the current status of the filarial and schistosome genome projects. Filarial Genome Project. Schistosome Genome Project. Parasitology. 118:1999;S19-S38. Suppl.
87. Dalton J.P., Mulcahy G. Parasite vaccines - a reality? Vet. Parasitol. 98:2001;149-167.
88. von Schrenck T. New approach to chronic inflammatory bowel diseases. Worm ova by prescription? MMW Fortschr. Med. 142:2000;16.
89. Mitsuyama K., Toyonaga A., Sata M. Cytokine-targeted therapeutic approaches for inflammatory bowel disease. Drugs Today (Barc.). 36:2000;281-293.
90. Travis S. Recent advances in immunomodulation in the treatment of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 15:2003;215-218.
91. Jonkers D., Stockbrugger R. Probiotics and inflammatory bowel disease. J. R. Soc. Med. 96:2002;167-171.